Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
BIO · against 163 other Healthcare companies of similar size
Ranked #77 of 164 · scores higher than 53% of peers · safety percentile 46
Bars: peers in each 10-point band of the safety percentile (higher = safer; 67+ earns the lower-risk grade)20 peers with a safety percentile of 40–49, including BIO · Click a bar to see the companies
Its metrics sit close to the Healthcare norm.
Risk is relative to the sector, not a bankruptcy probability. Banks and brokers carry high leverage by design, and share buybacks can shrink equity and current assets, which raises debt/equity on paper.
| Metric | BIO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Debt / equityLower is better · 159 reported | 0.19× | 0.34× | 63% | 33% | |
| BetaLower is better · 165 reported | 1.07 | 0.58 | 21% | 33% | |
| Current ratioHigher is better · 156 reported | 3.14× | 2.30× | 66% | 33% |
| Rank | Company | Market cap | Safety | Overall |
|---|---|---|---|---|
| 1 | 5.6B USD | 100 | 53 | |
| 1 | 6.6B USD | 100 | 45 | |
| 3 | 10.1B EUR (≈$11.1B) | 99 | ||
| 4 | 9.0B USD | 98 | 51 | |
| 5 | 5.7B USD | 97 | 52 | |
| 73 | 62.5B SEK (≈$6.3B) | 48 | 60 | |
| 74 | 7.0B USD | 48 | 63 | |
| 75 | 1.26T INR (≈$15.1B) | 48 | 63 | |
| 76 | 68.9B HKD (≈$8.8B) | 48 | 67 | |
| 77 | 10.0B USD | 46 | 43 | |
| 78 | 83.0B CNY (≈$11.6B) | 46 | 62 | |
| 79 | 1.85T JPY (≈$12.5B) | 46 | 55 | |
| 80 | 6.1B CHF (≈$7.0B) | 46 | 58 | |
| 81 | 1.42T JPY (≈$9.6B) | 45 | 50 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score